CHIMERIC THERAPEUTICS LIMITED — Director's Dealing 2023

Dec 14, 2023

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

	Chimeric Therapeutics Limited (ASX: CHM)
Name of Entity:
	68 638 835 828
ABN:

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Jennifer Chow
Date of Last Notice:	17 July 2023

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

irector” should be disclosed in this part.
Direct or Indirect Interest		Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.		Held via Broker nominee account
Date of change		14 December 2023
No. of securities held prior to change					Total 9,450,924 27,513,863 -
			Direct	Indirect	Total
		Shares	1,811,609	7,639,315	9,450,924
		Options	27,513,863	-	27,513,863
		Performance rights	-	-	-
Class		a) Fully Paid Ordinary Shares b) Unlisted Options c) Performance Rights
Number acquired					Total 8,643,603 15,139,467 4,062,997
			Direct	Indirect	Total
		Shares	-	a) 8,643,603	8,643,603
		Options	-	b) 15,139,467	15,139,467
		Performance rights	-	c) 4,062,997	4,062,997

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Confidential

Appendix 3Y Change of Director’s Interest Notice

Number disposed					Total - - -
			Direct	Indirect	Total
		Shares	-	-	-
		Options	-	-	-
		Performance rights	-	-	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation		a) $0.035 per share. b & c) Non-cash, see ‘nature of change’ below.
No. of securities held after change					Total 18,094,527 42,653,330 4,062,997
			Direct	Indirect	Total
		Shares	1,811,609	16,282,918	18,094,527
		Options	27,513,863	15,139,467	42,653,330
		Performance rights	-	4,062,997	4,062,997
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back		a) Issue of shares as part of sign-on payment for forfeiture of long-term incentive payment from previous employer as per section 9.8 of Prospectus lodged 18 January 2021. b & c) Issue of options and performance rights as approved by Chimeric Therapeutics shareholders at the Annual General Meeting held on 14 November 2023.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – Closed period

art 3 – Closed period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

If prior written clearance was N/A provided, on what date was this provided?

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 3